Intercept Pharma

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in Morristown, NJ.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The stock price of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) fell by 6.45% this past week. This is why it happened.

Intercept Pharmaceuticals Stock (ICPT): Why The Price Fell This Week

Investors need to pay close attention to Intercept (ICPT) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Intercept (ICPT) Stock?

Intercept (ICPT) withdraws its application seeking approval for OCA for the treatment of liver fibrosis due to nonalcoholic steatohepatitis in the EU. Resultantly, the stock declines.

Intercept (ICPT) Down on Withdrawal of Application for NASH

The stock price of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) fell by 14.87% today. This is why it happened.

Intercept Pharmaceuticals Stock (ICPT): Why The Price Fell Today

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) has withdrawn its European marketing application seeking approval for obeticholic acid (OCA) for liver fibrosis due to nonalcoholic steatohepatitis (NASH). The initial application was filed in December 2019 was supported by the interim analysis results from the Phase 3 REGENERATE study, which remains ongoing.

Why Are Intercept Pharmaceuticals Shares Falling Today?

NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has formally notified the European Medicines Agency (EMA) of its decision to withdraw its Marketing Authorization Application (MAA) for obeticholic acid (OCA) for the treatment of liver fibrosis due to nonalcoholic steatohepatitis (NASH).

Intercept Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock?

Intercept (ICPT) Down 10.7% Since Last Earnings Report: Can It Rebound?

Intercept Pharmaceuticals Inc (NASDAQ: ICPT) has announced results from a new analysis examining obeticholic acid's (OCA) potential to improve transplant-free survival in patients with primary biliary cholangitis (PBC). In the analysis, 209 patients treated with OCA in the POISE long-term safety extension study had significantly greater transplant-free survival than patients in the external control groups.

Intercept Posts Long-Term Data For Obeticholic Acid In Chronic Liver Disease Patients

Analysis compares findings from the long-term safety extension of the Phase 3 POISE trial to PBC natural history data from the Global PBC and UK-PBC databases

Intercept Announces New Long-Term Data Demonstrating Potential of Obeticholic Acid to Improve Transplant-Free Survival in Patients with PBC

NEW YORK, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept; M. Michelle Berrey, M.D., M.P.H., President of Research & Development and Chief Medical Officer of Intercept; Linda Richardson, Chief Commercial Officer of Intercept; and Andrew Saik, Chief Financial Officer of Intercept, will participate virtually in fireside chats at the following upcoming investor conferences:

Intercept to Present at Upcoming Investor Conferences

Intercept (ICPT) posts a narrower loss in the third quarter and sales beat estimates.

Intercept (ICPT) Beats on Q3 Earnings & Sales, Ups View

Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q3 2021 Results - Earnings Call Transcript

Worldwide Ocaliva® net sales of $92.8 million, representing 17% growth over the prior year quarter

Intercept Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

CRISPR Therapeutics

Ligand Pharmaceuticals

Novavax

Vaxart

Based on analysts' loftiest price targets, these drugmakers could double to nearly quintuple investors' money over the next 12 months.

5 Biotech Stocks With 105% to 386% Upside, According to Wall Street

Late-breaking oral presentation compares transplant-free survival in patients with PBC treated with OCA to external controls from the Global PBC and UK-PBC study groups

Intercept Announces Late-Breaking Oral Presentation and Poster Presentations at The Liver Meeting

Philadelphia, Pennsylvania--(Newsfile Corp. - October 23, 2021) - Kaskela Law LLC announces that it is investigating Intercept Pharmaceuticals, Inc. ("Intercept" or the "Company") (NASDAQ: ICPT) on behalf of the Company's stockholders.Recently an amended securities fraud complaint was filed against Intercept on behalf of investors who purchased shares of Intercept's common stock between September 27, 2019 and October 8, 2020. According to the complaint, during that time period Intercept and certain senior executive officers...

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Intercept Pharmaceuticals, Inc. (ICPT) and Encourages Long-Term ICPT Stockholders to Contact the Firm

The mean of analysts' price targets for Intercept (ICPT) points to a 94.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think Intercept (ICPT) Could Surge 95%: Read This Before Placing a Bet

Big 5 Sporting Goods

Blink Charging

Corsair Gaming

FuboTV

GoodRx Holdings

PetMed Express

Meme stocks are seeing a sudden increase in volume and price. Here are seven of the best meme stocks to buy.

7 Meme Stocks With Short-Squeeze Potential In October

Arcimoto

Greenidge Generation Holdings

iRobot

Lordstown Motors

SmileDirectClub

Workhorse Group

While betting on short-interest stocks has become a popular speculation tactic, you want to be careful about this fad. The post 7 Short-Interest Stocks That Could Be Bull Traps appeared first on InvestorPlace.

7 Short-Interest Stocks That Could Be Bull Traps

NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept, M. Michelle Berrey, M.D., M.P.H., President of Research & Development and Chief Medical Officer of Intercept, Linda Richardson, Chief Commercial Officer of Intercept, and Andrew Saik, Chief Financial Officer of Intercept, will present at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 8:40 a.m. ET.

Intercept to Present at the 2021 Cantor Virtual Global Healthcare Conference

SunPower

Off and on the price chart, these three most-shorted stocks – found after we've searched high and low – have the goods to rally. The post 3 Most-Shorted Stocks to Buy appeared first on InvestorPlace.

3 Most-Shorted Stocks to Buy

Amarin Corporation Plc

Inovio Pharmaceuticals

Plug Power

Zogenix

If these high-water price targets come to fruition, investors will be all smiles.

5 Stocks With 195% to 467% Upside, According to Wall Street

Gogo

GSX Techedu Inc.

Root

We're seeing loads of interest from investors targeting short-squeeze stocks this week as meme rallies push several shares higher. The post Short-Squeeze Stocks: Top 10 Stocks With High Short Interest This Week appeared first on InvestorPlace.

Short-Squeeze Stocks: Top 10 Stocks With High Short Interest This Week

NEW YORK, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer of Intercept, M. Michelle Berrey, M.D., M.P.H., President of Research & Development and Chief Medical Officer of Intercept, and Andrew Saik, Chief Financial Officer of Intercept, will present at the virtual Baird 2021 Global Healthcare Conference on Tuesday, September 14, 2021 at 10:15 a.m. ET.

Intercept to Present at the Virtual Baird 2021 Global Healthcare Conference

NEW YORK, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) (“Intercept”), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, announced today that it has entered into privately negotiated agreements with certain of the holders of its existing (i) 3.25% Convertible Senior Notes due 2023 (the “2023 Notes”) and (ii) 2.00% Convertible Senior Notes due 2026 (the “2026 Notes”) to exchange an aggregate of $306.5 million principal amount of 2023 Notes and an aggregate of $114.7 million principal amount of 2026 Notes for a newly issued series of Convertible Senior Secured Notes due 2026 (the “New Notes” and such transactions, the “Exchange”). Intercept will also sell approximately $117.6 million aggregate principal amount of New Notes for cash (the “Subscription” and, together with the Exchange, the “Transactions”). The Transactions are expected to close promptly, subject to and following customary closing conditions. In the aggregate, Intercept expects to issue approximately $500.0 million aggregate principal amount of New Notes to the participating holders.

News for Intercept Pharma Stock (ICPT)